Author: Josh Blacher
Mr. Blacher joined InMed Pharmaceuticals (TSX:IN; OTCQX:IMLFF) in 2018, bringing two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with the investment community. Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (NASDAQ:TRPX) and Galmed Pharmaceuticals (NASDAQ:GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in Mergers & Acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.